Navigation Links
Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
Date:6/16/2009

Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite generic erosion of key brands, the hospital-acquired gram-negative infections drug market will increase by $1 billion from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Gram Negative Infections finds that the introduction and uptake of next-generation cephalosporins, carbapenems, quinolones, and beta-lactam/beta-lactamase inhibitors, will be a significant driver of market growth through 2018. Among these emerging therapies, Novexel's NXL-104/ceftazidime, a novel beta-lactam/beta-lactamase inhibitor agent, is positioned to offer the most significant advance in the treatment of hospital-acquired gram-negative infections and will earn more than $250 million in sales in 2018. Additionally, the continued uptake of two recent market entrants -- Johnson & Johnson's Doribax and, to a lesser extent, Wyeth's Tygacil -- will also drive the market. Although these three agents and several other emerging therapies will drive market growth, generic erosion of key brands will temper overall market sales through 2018, according to the report.

Generic erosion of top branded products such as piperacillin/tazobactam (Wyeth's Zosyn/Tazocin), imipenem/cilastatin (Merck's Primaxin/Tienam), meropenem (Cubist Pharmaceuticals/AstraZeneca's Merrem/Meronem) and levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit) will have the greatest impact on the market. In 2008, these four products accounted for approximately 50 percent of the hospital-acquired gram-negative infections market. The report forecasts that, in 2018, generic erosion will reduce the combined sales of these agents to approximately 25 percent of the market.

The report also finds that drug development for gram-negative infections has been slow and overshadowed by interest and investment in developing novel therapies for the more lucrative market of hospital-acquired infections due to gram-positive pathogens, namely, methicillin-resistant Staphylococcus aureus (MRSA). However, as competition increases and opportunities decline in the market for hospital-acquired infections due to MRSA, the hospital-acquired gram-negative infections market segment is ripe with attractive drug development opportunities.

"Competition between agents is relatively low in the hospital-acquired gram-negative infections market when compared with the market for hospital-acquired infections due to gram-positive pathogens," said Decision Resources Analyst Hemali Patel, Ph.D. "Minimal competition in the late-stage pipeline and high unmet need will allow novel agents with clearly demonstrated efficacy against key gram-negative pathogens to command a high price and favorable formulary position -- two key attributes that underlie commercial success in this market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Despite overeating, morbidly obese mice gain protection against diabetes
2. Despite grumbling, most Americans say they are happy at work
3. Most patients who have male-to-female sex-change surgery are happy, despite complications
4. Cataract Surgery: A Bargain, Despite the Price
5. UGA study: Youth exposed to smokeless tobacco ads despite settlement
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
8. A Full and Long Life, Despite Diabetes
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
11. Miscarriage myths persist despite prevalence of medical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: